France bans use of hydroxychloroquine to treat Covid-19

Published May 27, 2020
A nurse shows a pill of hydroxychloroquine, amid the coronavirus outbreak at Nossa Senhora da Conceicao hospital in Porto Alegre, Brazil. — Reuters/File
A nurse shows a pill of hydroxychloroquine, amid the coronavirus outbreak at Nossa Senhora da Conceicao hospital in Porto Alegre, Brazil. — Reuters/File

The French government on Wednesday cancelled a decree allowing hospital doctors to administer hydroxychloroquine as a treatment to patients suffering severe forms of Covid-19, the illness caused by the new coronavirus.

The announcement comes two days after the World Health Organisation said it was pausing a large trial of the malaria drug due to safety concerns.

British medical journal The Lancet has reported that patients getting hydroxychloroquine had increased death rates and irregular heartbeats, adding to a series of other disappointing results for the drug as a way to treat Covid-19.

US President Donald Trump and others have pushed hydroxychloroquine in recent months as a possible coronavirus treatment.

France decided at the end of March to allow the use of hydroxychloroquine in specific situations and in hospitals only.

No vaccine or treatment has yet been approved to treat Covid-19 which has killed more than 350,000 people globally.

The WHO "has implemented a temporary pause ... while the safety data is reviewed", its chief Tedros Adhanom Ghebreyesus said on Monday, referring to the hydroxychloroquine arm of a global trial of various possible treatments.

Trump announced last week he was taking the drug, explaining he had decided to take after receiving letters from a doctor and other people advocating it.

"I think it's good. I've heard a lot of good stories," Trump told reporters then, as he declared it safe.

Trump dismissed the opinions then of his own government's experts who had warned of the serious risks associated with hydroxychloroquine, with the Food and Drug Administration highlighting reported poisonings and heart problems.

Opinion

Editorial

Missing in action
17 Mar, 2026

Missing in action

NOT exactly known for playing a proactive role in protecting the interests of Muslim nations and populations...
Risk to stability
Updated 17 Mar, 2026

Risk to stability

THE risks to Pakistan’s fragile economic recovery from the US-Israel war on Iran cannot be dismissed. Yet the...
Enrolment push
17 Mar, 2026

Enrolment push

THE federal government has embarked upon the welcome initiative to enrol 25,000 out-of-school children in Islamabad...
Holding the line
16 Mar, 2026

Holding the line

PAKISTAN’S long battle against polio has recently produced encouraging signs. Data from the national eradication...
Power self-reliance
Updated 16 Mar, 2026

Power self-reliance

PAKISTAN’S transition to domestic sources of electricity is a welcome development for a country that has long been...
Looking for safety
16 Mar, 2026

Looking for safety

AS the Middle East conflict enters its third week, the war’s most enduring victims are not those who wage it....